Last reviewed · How we verify
NCT01582763: IGOS
International Guillain-Barré Syndrome Outcome Study
trial in Guillain-Barré Syndrome in 2,000 participants. Completed in 2 December 2024.
1 September 2024
Quick facts
| Lead sponsor | Erasmus Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 1 May 2012 |
| Primary completion | 1 September 2024 |
| Estimated completion | 2 December 2024 |
| Sites | 138 locations across Italy, Japan, Malaysia, Taiwan, Denmark, Netherlands, Belgium, United States |
Conditions studied
- Guillain-Barré Syndrome — all drugs for Guillain-Barré Syndrome →
- Miller Fisher Syndrome — all drugs for Miller Fisher Syndrome →
Sponsor
Erasmus Medical Center
Who can join
Eligibility, any sex, with Guillain-Barré Syndrome or Miller Fisher Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
International GBS Outcome Study (IGOS) is a study conducted by the members of the Inflammatory Neuropathy Consortium (INC) and Peripheral Nerve Society (PNS) on disease course and outcome in Guillain-Barré syndrome (GBS). The IGOS aims to identify clinical and biological determinants and predictors of disease course and outcome in individual patients with Guillain-Barré syndrome, as early as possible after onset of disease.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Antibodies to watch in 2025.
Crescioli S, Kaplon H, Wang L, Visweswaraiah J, et al · · 2025 · cited 87× · PMID 39711140 · DOI 10.1080/19420862.2024.2443538 -
Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.
Doets AY, Lingsma HF, Walgaard C, Islam B, et al · · 2022 · cited 49× · PMID 34937789 · DOI 10.1212/wnl.0000000000013139 -
Measurement properties of the Inflammatory Rasch-built Overall Disability Scale (I-RODS) in patients with Guillain-Barré syndrome.
Pelouto F, Papri N, Haagsma JA, Cornblath DR, et al · · 2026 · PMID 41739223 · DOI 10.1007/s00415-026-13684-6
Verify or expand the search:
- PubMed search for NCT01582763
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Guillain-Barré Syndrome
Currently open trials in the same condition.
- NCT05461898 — RehabGBs: Rehabilitation in People With Guillain-Barré Syndrome · NA · recruiting
Other Erasmus Medical Center trials
Trials by the same sponsor.
- NCT07406269 — Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery · NA · not yet recruiting
- NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
- NCT07383194 — Prediction Models for LDLT Outcomes · not yet recruiting
- NCT07426575 — Evaluating the Usability of New Dialysis Bags · not yet recruiting
- NCT07329296 — The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01582763 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Erasmus Medical Center
- Last refreshed: 12 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01582763.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing